MetaCap

ProMIS Neurosciences (PMN) vs Serina Therapeutics (SER)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ProMIS Neurosciences (PMN) has outperformed Serina Therapeutics (SER) over the past year, losing 69.9% versus a loss of 71.9%. Over five years, SER leads with a -95.6% price change compared with -98.2% for PMN. Serina Therapeutics is the larger company by market cap ($29.8 million vs $28.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PMN-69.90%SER-71.93%
+146%+32%-82%
Nov 21, 20251 yearNov 20, 2026
PMN-98.38%SER-96.03%
+46%-30%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PMN versus SER key metrics
MetricPMNSER
Share price$3.16$1.12
Market cap$28.43M$29.76M
1-day change-1.56%-6.67%
YTD return-53.73%-41.45%
1-year return-69.90%-71.93%
5-year return-98.24%-95.64%
EPS (TTM)$-6.50$-1.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$130.00K
Revenue growth (YoY)—+132.14%
Net income (latest FY)$-39.72M$-19.18M
Operating margin—-18478.46%
Net margin—-14755.38%
52-week high$27.40$4.26
52-week low$2.78$1.06
Distance from 52-week high-88.47%-73.71%
Analyst consensusnonenone
Avg. price target upside+1248.42%+748.21%
Average volume164.88K68.98K
Shares outstanding9.00M26.57M
Employees1016
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About ProMIS Neurosciences

PMN stock →

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About Serina Therapeutics

SER stock →

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

PMN vs SER FAQ

Which is bigger, ProMIS Neurosciences or Serina Therapeutics?

Serina Therapeutics (SER) is larger, with a market capitalization of $29.76M compared with $28.43M for ProMIS Neurosciences (PMN).

Which stock has performed better over the past year, PMN or SER?

PMN returned -69.90% over the past 12 months, compared with -71.93% for SER (price return, excluding dividends). Past performance does not predict future results.

Are ProMIS Neurosciences and Serina Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons